Scorpion Therapeutics rakes in $108m Series A

Scorpion Therapeutics Inc, a next-generation precision oncology company, has secured $108 million in Series A financing.

Scorpion Therapeutics Inc, a next-generation precision oncology company, has secured $108 million in Series A financing. Atlas Venture, Omega Funds and Vida Ventures led the round with participation from Abingworth and Partners HealthCare Innovation.

Source: Press Release